Source link : https://www.newshealth.biz/health-news/nemolizumab-gets-fda-nod-for-atopic-dermatitis/
The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately controlled with topical therapies in patients aged 12 years and older, according to a press release from the manufacturer, Galderma. Nemolizumab (Nemluvio), a monoclonal antibody administered subcutaneously, targets the interleukin-31 (IL-31) receptor. IL-31 is known to promote itching and inflammation […]
Author : News Health
Publish date : 2024-12-15 17:22:35
Copyright for syndicated content belongs to the linked Source.